How to buy Kiniksa Pharmaceuticals stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kiniksa Pharmaceuticals stock

Own Kiniksa Pharmaceuticals stock in just a few minutes.

Kiniksa Pharmaceuticals, Ltd is a biotechnology business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Kiniksa Pharmaceuticals employs 168 staff and has a market cap (total outstanding shares value) of USD$1.5 billion.

How to buy shares in Kiniksa Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Kiniksa Pharmaceuticals. Find the stock by name or ticker symbol: KNSA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kiniksa Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kiniksa Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Kiniksa Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kiniksa Pharmaceuticals share price

Use our graph to track the performance of KNSA stocks over time.

Kiniksa Pharmaceuticals shares at a glance

Information last updated 2021-03-18.
52-week rangeUSD$11.51 - USD$26.135
50-day moving average USD$21.8312
200-day moving average USD$18.5381
Wall St. target priceUSD$34
PE ratio 5.0867
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.339

Buy Kiniksa Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kiniksa Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Kiniksa Pharmaceuticals under- or over-valued?

Valuing Kiniksa Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kiniksa Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Kiniksa Pharmaceuticals's P/E ratio

Kiniksa Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Kiniksa Pharmaceuticals shares trade at around 5x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Kiniksa Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -32.57%
Return on equity TTM -60.07%
Profit margin 0%
Book value $4.573
Market capitalisation USD$1.5 billion

TTM: trailing 12 months

Shorting Kiniksa Pharmaceuticals shares

There are currently 3.9 million Kiniksa Pharmaceuticals shares held short by investors – that's known as Kiniksa Pharmaceuticals's "short interest". This figure is 2.1% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting Kiniksa Pharmaceuticals shares can be evaluated.

Kiniksa Pharmaceuticals's "short interest ratio" (SIR)

Kiniksa Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Kiniksa Pharmaceuticals shares currently shorted divided by the average quantity of Kiniksa Pharmaceuticals shares traded daily (recently around 347488.4097035). Kiniksa Pharmaceuticals's SIR currently stands at 11.13. In other words for every 100,000 Kiniksa Pharmaceuticals shares traded daily on the market, roughly 11130 shares are currently held short.

However Kiniksa Pharmaceuticals's short interest can also be evaluated against the total number of Kiniksa Pharmaceuticals shares, or, against the total number of tradable Kiniksa Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kiniksa Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Kiniksa Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.1364% of the tradable shares (for every 100,000 tradable Kiniksa Pharmaceuticals shares, roughly 136 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kiniksa Pharmaceuticals.

Find out more about how you can short Kiniksa Pharmaceuticals stock.

Kiniksa Pharmaceuticals share dividends

We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.

Kiniksa Pharmaceuticals share price volatility

Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $11.51 up to $26.135. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is 0. This would suggest that Kiniksa Pharmaceuticals's shares are less volatile than average (for this exchange).

Kiniksa Pharmaceuticals overview

Kiniksa Pharmaceuticals, Ltd. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site